 Lisa Forman
Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 29 | 2024 | 833 | 3.880 |
Why?
| | Cholangitis, Sclerosing | 9 | 2025 | 71 | 2.190 |
Why?
| | Hepatitis C | 8 | 2021 | 243 | 1.430 |
Why?
| | Graft Rejection | 6 | 2024 | 598 | 1.330 |
Why?
| | End Stage Liver Disease | 3 | 2024 | 79 | 1.220 |
Why?
| | Graft Survival | 7 | 2024 | 513 | 0.900 |
Why?
| | Social Determinants of Health | 2 | 2024 | 226 | 0.880 |
Why?
| | Cannabinoids | 1 | 2021 | 154 | 0.630 |
Why?
| | Hepatitis, Autoimmune | 1 | 2018 | 20 | 0.600 |
Why?
| | Thrombosis | 1 | 2021 | 348 | 0.560 |
Why?
| | Aspartate Aminotransferases | 1 | 2017 | 88 | 0.550 |
Why?
| | Living Donors | 7 | 2023 | 286 | 0.550 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 430 | 0.540 |
Why?
| | Alanine Transaminase | 1 | 2017 | 153 | 0.530 |
Why?
| | Hepatitis C, Chronic | 4 | 2015 | 156 | 0.530 |
Why?
| | Hodgkin Disease | 1 | 2017 | 134 | 0.490 |
Why?
| | Glucocorticoids | 2 | 2018 | 580 | 0.470 |
Why?
| | Hepacivirus | 4 | 2021 | 239 | 0.470 |
Why?
| | Gastroenterology | 2 | 2009 | 175 | 0.420 |
Why?
| | Waiting Lists | 4 | 2024 | 237 | 0.380 |
Why?
| | Liver Cirrhosis, Biliary | 2 | 2023 | 18 | 0.370 |
Why?
| | Liver | 3 | 2017 | 1842 | 0.340 |
Why?
| | Recurrence | 7 | 2023 | 1011 | 0.340 |
Why?
| | Pruritus | 3 | 2025 | 58 | 0.340 |
Why?
| | Liver Diseases | 3 | 2019 | 290 | 0.320 |
Why?
| | Antiviral Agents | 4 | 2015 | 715 | 0.320 |
Why?
| | Treatment Outcome | 14 | 2024 | 10219 | 0.310 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2739 | 0.300 |
Why?
| | Healthcare Disparities | 2 | 2024 | 578 | 0.290 |
Why?
| | Liver Failure | 3 | 2008 | 91 | 0.280 |
Why?
| | Humans | 47 | 2025 | 129625 | 0.270 |
Why?
| | Liver Cirrhosis | 3 | 2015 | 281 | 0.260 |
Why?
| | Fibrosis | 1 | 2008 | 526 | 0.250 |
Why?
| | Middle Aged | 23 | 2025 | 31136 | 0.230 |
Why?
| | Health Care Rationing | 2 | 2004 | 57 | 0.230 |
Why?
| | Foreign-Body Migration | 1 | 2004 | 34 | 0.220 |
Why?
| | Ribavirin | 2 | 2005 | 91 | 0.220 |
Why?
| | Cholestasis | 2 | 2025 | 232 | 0.220 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 1 | 2004 | 14 | 0.220 |
Why?
| | Tissue Donors | 4 | 2013 | 391 | 0.220 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2004 | 41 | 0.220 |
Why?
| | Resource Allocation | 1 | 2004 | 39 | 0.210 |
Why?
| | Interferon-alpha | 2 | 2005 | 194 | 0.210 |
Why?
| | Patient Selection | 4 | 2013 | 661 | 0.210 |
Why?
| | Heart Atria | 1 | 2004 | 129 | 0.210 |
Why?
| | Registries | 4 | 2025 | 1899 | 0.200 |
Why?
| | Insurance | 1 | 2023 | 13 | 0.200 |
Why?
| | Berberine | 1 | 2022 | 6 | 0.200 |
Why?
| | Adult | 21 | 2025 | 35599 | 0.200 |
Why?
| | Aged | 14 | 2025 | 22061 | 0.190 |
Why?
| | Cannabidiol | 1 | 2024 | 108 | 0.190 |
Why?
| | Cholangiocarcinoma | 1 | 2022 | 77 | 0.190 |
Why?
| | Retrospective Studies | 14 | 2025 | 14522 | 0.190 |
Why?
| | Dronabinol | 1 | 2024 | 203 | 0.190 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2021 | 17 | 0.190 |
Why?
| | Bile Duct Neoplasms | 1 | 2022 | 99 | 0.180 |
Why?
| | Male | 26 | 2025 | 63670 | 0.180 |
Why?
| | Female | 25 | 2025 | 68734 | 0.180 |
Why?
| | Transplant Recipients | 1 | 2021 | 163 | 0.160 |
Why?
| | Thiazoles | 1 | 2000 | 117 | 0.160 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2024 | 325 | 0.160 |
Why?
| | Thiazolidinediones | 1 | 2000 | 137 | 0.150 |
Why?
| | Primary Health Care | 1 | 2009 | 1686 | 0.150 |
Why?
| | Postoperative Complications | 3 | 2011 | 2477 | 0.150 |
Why?
| | Parkinson Disease | 1 | 2024 | 461 | 0.150 |
Why?
| | Withholding Treatment | 1 | 2018 | 71 | 0.140 |
Why?
| | Ursodeoxycholic Acid | 3 | 2023 | 19 | 0.140 |
Why?
| | Time Factors | 6 | 2018 | 6555 | 0.140 |
Why?
| | Biopsy | 3 | 2017 | 1088 | 0.140 |
Why?
| | Models, Theoretical | 1 | 2001 | 546 | 0.140 |
Why?
| | Risk Factors | 7 | 2024 | 9786 | 0.130 |
Why?
| | United States | 6 | 2025 | 13871 | 0.130 |
Why?
| | Aortic Valve Insufficiency | 1 | 2015 | 46 | 0.120 |
Why?
| | Hepatic Artery | 2 | 2004 | 59 | 0.110 |
Why?
| | Alkaline Phosphatase | 3 | 2023 | 146 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 121 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1432 | 0.100 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1685 | 0.100 |
Why?
| | Cholangitis | 1 | 2013 | 20 | 0.100 |
Why?
| | Transplantation | 1 | 2013 | 31 | 0.100 |
Why?
| | Aortic Valve Stenosis | 1 | 2015 | 218 | 0.100 |
Why?
| | Hepatitis C Antibodies | 1 | 2012 | 11 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 260 | 0.100 |
Why?
| | DEAD-box RNA Helicases | 1 | 2013 | 66 | 0.100 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2004 | 272 | 0.090 |
Why?
| | Bile Acids and Salts | 2 | 2023 | 195 | 0.090 |
Why?
| | Interleukins | 1 | 2013 | 241 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2000 | 1221 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1164 | 0.090 |
Why?
| | Hepatitis B, Chronic | 1 | 2010 | 18 | 0.080 |
Why?
| | Hepatitis B Vaccines | 1 | 2010 | 47 | 0.080 |
Why?
| | Duodenostomy | 1 | 2009 | 3 | 0.080 |
Why?
| | Gallbladder | 1 | 2009 | 17 | 0.080 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2009 | 27 | 0.080 |
Why?
| | Immunoglobulins | 1 | 2010 | 161 | 0.080 |
Why?
| | Proportional Hazards Models | 4 | 2015 | 1198 | 0.080 |
Why?
| | Liver Neoplasms | 2 | 2004 | 639 | 0.080 |
Why?
| | Disease Progression | 3 | 2015 | 2627 | 0.070 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2008 | 24 | 0.070 |
Why?
| | Postoperative Care | 1 | 2009 | 241 | 0.070 |
Why?
| | Physicians, Family | 1 | 2009 | 206 | 0.070 |
Why?
| | Hepatectomy | 1 | 2009 | 212 | 0.070 |
Why?
| | Coronary Disease | 2 | 2001 | 385 | 0.070 |
Why?
| | Medicine | 1 | 2009 | 119 | 0.070 |
Why?
| | Prevalence | 3 | 2025 | 2564 | 0.070 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 273 | 0.070 |
Why?
| | Survival Analysis | 3 | 2004 | 1269 | 0.060 |
Why?
| | Donor Selection | 1 | 2006 | 75 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2060 | 0.060 |
Why?
| | Duodenal Diseases | 1 | 2004 | 8 | 0.060 |
Why?
| | Metabolic Syndrome | 1 | 2008 | 340 | 0.060 |
Why?
| | Intestinal Fistula | 1 | 2004 | 15 | 0.060 |
Why?
| | Vascular Fistula | 1 | 2004 | 22 | 0.060 |
Why?
| | Aneurysm, False | 1 | 2004 | 47 | 0.060 |
Why?
| | Quality of Life | 2 | 2023 | 2688 | 0.060 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2004 | 48 | 0.060 |
Why?
| | Radiography, Interventional | 1 | 2004 | 105 | 0.050 |
Why?
| | Delayed Diagnosis | 1 | 2024 | 79 | 0.050 |
Why?
| | Calcineurin Inhibitors | 1 | 2003 | 68 | 0.050 |
Why?
| | Cholagogues and Choleretics | 1 | 2023 | 8 | 0.050 |
Why?
| | Tissue and Organ Procurement | 2 | 2004 | 289 | 0.050 |
Why?
| | Acetates | 1 | 2023 | 100 | 0.050 |
Why?
| | Hepatocytes | 1 | 2003 | 216 | 0.050 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2022 | 65 | 0.050 |
Why?
| | Genotype | 3 | 2015 | 1833 | 0.050 |
Why?
| | Effect Modifier, Epidemiologic | 1 | 2002 | 12 | 0.050 |
Why?
| | Vancomycin | 1 | 2023 | 77 | 0.050 |
Why?
| | Sirolimus | 1 | 2003 | 270 | 0.050 |
Why?
| | Vaccination | 1 | 2010 | 1347 | 0.050 |
Why?
| | Echocardiography | 1 | 2004 | 634 | 0.040 |
Why?
| | Survival Rate | 2 | 2004 | 1872 | 0.040 |
Why?
| | Reoperation | 1 | 2003 | 541 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2004 | 1843 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2015 | 1499 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2024 | 1213 | 0.040 |
Why?
| | Stents | 1 | 2004 | 504 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 1001 | 0.040 |
Why?
| | Verapamil | 1 | 2000 | 41 | 0.040 |
Why?
| | Pravastatin | 1 | 2000 | 40 | 0.040 |
Why?
| | Chenodeoxycholic Acid | 1 | 2019 | 14 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1875 | 0.040 |
Why?
| | Coronary Artery Bypass | 1 | 2001 | 224 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2009 | 5415 | 0.040 |
Why?
| | Drug Interactions | 1 | 2000 | 395 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1592 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2000 | 265 | 0.040 |
Why?
| | Cohort Studies | 2 | 2012 | 5426 | 0.040 |
Why?
| | RNA, Viral | 2 | 2015 | 620 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2024 | 903 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2000 | 1203 | 0.030 |
Why?
| | North America | 1 | 2017 | 292 | 0.030 |
Why?
| | Ischemia | 1 | 2000 | 406 | 0.030 |
Why?
| | Prognosis | 2 | 2004 | 3774 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2008 | 2006 | 0.030 |
Why?
| | Chronic Disease | 1 | 2001 | 1720 | 0.030 |
Why?
| | Thrombelastography | 1 | 2015 | 150 | 0.030 |
Why?
| | Femoral Artery | 1 | 2015 | 174 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 515 | 0.030 |
Why?
| | DEAD Box Protein 58 | 1 | 2013 | 9 | 0.030 |
Why?
| | Viral Load | 1 | 2015 | 449 | 0.030 |
Why?
| | Pennsylvania | 1 | 2013 | 108 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1705 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 851 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2013 | 4894 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 1994 | 533 | 0.020 |
Why?
| | Depression | 1 | 2001 | 1317 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 2013 | 217 | 0.020 |
Why?
| | Interferons | 1 | 2013 | 191 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 360 | 0.020 |
Why?
| | Length of Stay | 2 | 2009 | 1122 | 0.020 |
Why?
| | Hepatitis B virus | 1 | 2010 | 36 | 0.020 |
Why?
| | Immunization, Passive | 1 | 2010 | 86 | 0.020 |
Why?
| | Risk Assessment | 2 | 2013 | 3262 | 0.020 |
Why?
| | Cholangiography | 1 | 2009 | 17 | 0.020 |
Why?
| | Risk | 1 | 2012 | 855 | 0.020 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 47 | 0.020 |
Why?
| | Anastomosis, Surgical | 1 | 2009 | 149 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2010 | 219 | 0.020 |
Why?
| | DNA, Viral | 1 | 2010 | 347 | 0.020 |
Why?
| | Hypertension, Portal | 1 | 2008 | 61 | 0.020 |
Why?
| | Medical Records | 1 | 2008 | 170 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 787 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5075 | 0.020 |
Why?
| | Preoperative Care | 1 | 2008 | 338 | 0.020 |
Why?
| | Mental Disorders | 1 | 1994 | 1034 | 0.020 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2000 | 2442 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 1970 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2013 | 3378 | 0.010 |
Why?
| | Survival | 1 | 2004 | 38 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2274 | 0.010 |
Why?
| | alpha-Fetoproteins | 1 | 2004 | 42 | 0.010 |
Why?
| | Microsomes, Liver | 1 | 2003 | 87 | 0.010 |
Why?
| | Comorbidity | 1 | 2008 | 1547 | 0.010 |
Why?
| | Probability | 1 | 2004 | 306 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4404 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 2004 | 402 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 263 | 0.010 |
Why?
| | Tacrolimus | 1 | 2003 | 193 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2005 | 1308 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 12455 | 0.010 |
Why?
| | Observation | 1 | 2001 | 51 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2004 | 1282 | 0.010 |
Why?
| | Health Surveys | 1 | 2001 | 493 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 858 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 1947 | 0.010 |
Why?
| | Prospective Studies | 1 | 2008 | 7135 | 0.010 |
Why?
| | Models, Biological | 1 | 2003 | 1724 | 0.010 |
Why?
| | Patient Readmission | 1 | 2001 | 653 | 0.010 |
Why?
| | History, 17th Century | 1 | 1994 | 14 | 0.010 |
Why?
| | History, 18th Century | 1 | 1994 | 18 | 0.010 |
Why?
| | History, Ancient | 1 | 1994 | 52 | 0.010 |
Why?
| | History, 19th Century | 1 | 1994 | 59 | 0.010 |
Why?
| | Europe | 1 | 1994 | 363 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2001 | 2720 | 0.010 |
Why?
| | History, 20th Century | 1 | 1994 | 294 | 0.010 |
Why?
| | Adolescent | 1 | 2006 | 20412 | 0.000 |
Why?
|
|
Forman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|